UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V.

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against uniQure N.V. for possible violations of federal securities laws and unlawful business practices following a significant drop in share price due to FDA concerns regarding AMT-130 [1][2]. Investigation Details - On November 3, 2025, uniQure announced that the FDA no longer believes that data from Phase I/II studies of AMT-130 may be adequate for a Biologics License Application (BLA) submission, leading to a lack of clarity on the timing of the BLA submission [2]. - Following this announcement, uniQure's shares fell by over 57% during morning trading on the same day [2]. Next Steps - Investors who purchased or acquired uniQure shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3].